AbbVie inks $10.9B Apogee buyout to bag eczema prospect
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AbbVie inks $10.9B Apogee buyout to bag eczema prospect" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Business Journals and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 11d ago.
Quick answers
Why is "AbbVie inks $10.9B Apogee buyout to bag eczema prospect" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- AbbVie seals $10.9B deal to acquire Waltham biotech Apogee Therapeutics The Business Journals · 50d ago
- AbbVie said to be reeling in Apogee and its Dupixent rival for almost $11B: report FirstWord Pharma · 50d ago
Topics
Related trends
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.
Lilly, J&J and AbbVie Hit New Highs
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today’s Market
Market analysts are tracking shifting volatility and AI-driven growth as investors focus on semiconductor and aerospace stocks.
AbbVie’s biggest deal since 2019 could land soon
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.